These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in the economy and the markets. The DJIA itself gained 14% in 2024, far underperforming the larger and more diverse S&P 500, which gained 25%.

The 2024 losers

The five stocks at the bottom of the barrel, which pulled down the winners, were in fact, losers. Not only were they the tail of a year with growth, but they all lost value over the year. In order of best to worst, the list includes Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), Amgen (NASDAQ: AMGN), Nike (NYSE: NKE), and Boeing (NYSE: BA).

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

NKE data by YCharts

I don't think you can blame these companies' woes on a specific, overarching factor like high interest rates or macroeconomic volatility. Boeing has had many problems, starting with the more general pandemic-related issues like low demand and inflation, and there were major safety concerns last year. It culminated in a new CEO, and investors are waiting to see what's in store this year.

Nike has let competitors cut into its market share and has seen its sales decline. It also just got a new CEO, and the market is waiting for another update. Amgen, Merck, and Johnson & Johnson are all healthcare stocks and often move based on news about drug performance and new products.

The bright side of the equation for all of these companies is that excepting Boeing, they all pay dividends, and Johnson & Johnson is a dividend king. Dividend stocks aren't growth stocks, and investors buy them for reliable passive income. At the current prices, the dividend yields are quite high.

As industry leaders, they can add value to your portfolio through passive income, and if you have confidence in a rebound, you can scoop them up at a great price.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $381,744!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,357!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $531,127!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of January 21, 2025

Jennifer Saibil has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Nike. The Motley Fool recommends Amgen and Johnson & Johnson. The Motley Fool has a disclosure policy.